{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:54:38Z","timestamp":1781978078837,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jvs.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:30:47Z","timestamp":1770337847000},"page":"1661-1670.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7571-3905","authenticated-orcid":false,"given":"Joshua","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahman","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan T.P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-7367","authenticated-orcid":false,"given":"Alan","family":"Dardik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2026.02.003_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1681\/ASN.2018050531","article-title":"Projecting ESRD incidence and prevalence in the United States through 2030","volume":"30","author":"McCullough","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jvs.2026.02.003_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.21037\/cdt-21-565","article-title":"Surgical creation of upper extremity arteriovenous fistula and grafts: a narrative review","volume":"13","author":"Montelongo","year":"2023","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.jvs.2026.02.003_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/1129729819845562","article-title":"Factors affecting arteriovenous fistula dysfunction: a narrative review","volume":"21","author":"Gameiro","year":"2020","journal-title":"J Vasc Access"},{"key":"10.1016\/j.jvs.2026.02.003_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2215\/CJN.02950707","article-title":"Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative","volume":"3","author":"Huijbregts","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jvs.2026.02.003_bib5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamasurg.2021.4527","article-title":"Arteriovenous fistula maturation, functional patency, and intervention rates","volume":"156","author":"Huber","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jvs.2026.02.003_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/11297298211018062","article-title":"Ultrasound evaluation of access complications: thrombosis, aneurysms, pseudoaneurysms and infections","volume":"22","author":"Meola","year":"2021","journal-title":"J Vasc Access"},{"key":"10.1016\/j.jvs.2026.02.003_bib7","article-title":"Hemodialysis access type and access patency loss: an observational cohort Study","volume":"5","author":"Roetker","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.jvs.2026.02.003_bib8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/cells13191637","article-title":"The role of cardio-renal inflammation in deciding the fate of the arteriovenous fistula in haemodialysis therapy","volume":"13","author":"Kane","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jvs.2026.02.003_bib9","doi-asserted-by":"crossref","first-page":"H241","DOI":"10.1152\/ajpheart.00010.2025","article-title":"Cellular and molecular mechanisms underlying hemodialysis arteriovenous fistula dysfunction and approaches to promote maturation: a vascular perspective","volume":"329","author":"Shiu","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jvs.2026.02.003_bib10","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.3390\/ijms25179519","article-title":"The pathological mechanisms and therapeutic molecular targets in arteriovenous fistula dysfunction","volume":"25","author":"Yan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jvs.2026.02.003_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2026.02.003_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2026.02.003_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide-1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jvs.2026.02.003_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jvs.2026.02.003_bib15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s13300-021-01198-5","article-title":"Glucagon-like peptide-1 receptor agonist use in people living with type 2 diabetes mellitus and chronic kidney disease: a narrative review of the key evidence with practical consideration","volume":"13","author":"Gorriz","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jvs.2026.02.003_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.jvs.2026.02.003_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2021.103847","article-title":"Assessing real-world medication data completeness","volume":"119","author":"Evans","year":"2021","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jvs.2026.02.003_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jcjd.2018.05.008","article-title":"Semaglutide: review and place in therapy for adults with type 2 diabetes","volume":"43","author":"Goldenberg","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jvs.2026.02.003_bib19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jvs.2026.02.003_bib20","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jvs.2026.02.003_bib21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jvs.2023.12.031","article-title":"Characterization of long-term survival in Medicare patients undergoing arteriovenous hemodialysis access","volume":"79","author":"Smeds","year":"2024","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.003_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2026.02.003_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.avsg.2020.04.009","article-title":"Impact of body mass index on outcomes of autogenous fistulas for hemodialysis access","volume":"68","author":"Arhuidese","year":"2020","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.003_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.avsg.2023.05.037","article-title":"Predictors of arteriovenous fistula maturation among patients with severe obesity","volume":"97","author":"Anderson","year":"2023","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.003_bib25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jvs.2018.12.041","article-title":"Preoperative hemoglobin A1c level and increased risk of adverse limb events in diabetic patients undergoing infrainguinal lower extremity bypass surgery in the Vascular Quality Initiative","volume":"70","author":"Singh","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.003_bib26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jvs.2019.11.048","article-title":"Poor glycemic control is associated with significant increase in major limb amputation and adverse events in the 30-day postoperative period after infrainguinal bypass","volume":"72","author":"McGinigle","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.003_bib27","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jvs.2026.02.003_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2012.11.057","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury","volume":"699","author":"Hirata","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jvs.2026.02.003_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12933-017-0603-x","article-title":"The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis","volume":"16","author":"Kushima","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jvs.2026.02.003_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcin.2022.10.062","article-title":"Cause-specific mortality in patients with advanced chronic kidney disease in the ISCHEMIA-CKD trial","volume":"16","author":"Sidhu","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2026.02.003_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jvs.2026.02.003_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jvs.2026.02.003_bib33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.avsg.2023.02.005","article-title":"The effect of obesity on outcomes after arteriovenous fistula creation: a systematic review","volume":"92","author":"Lee","year":"2023","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.jvs.2026.02.003_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/0886022X.2018.1456464","article-title":"A meta-analysis of the association between diabetic patients and arteriovenous fistula failure in dialysis","volume":"40","author":"Yan","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.jvs.2026.02.003_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.30952","article-title":"GLP-1 RAs and cardiovascular and kidney outcomes by body mass index in type 2 diabetes","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jvs.2026.02.003_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jvs.2026.02.003_bib37","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.metabol.2013.04.010","article-title":"GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways","volume":"62","author":"Aronis","year":"2013","journal-title":"Metabolism"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521426000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521426000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T14:26:34Z","timestamp":1779978394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521426000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0741521426000911"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2026.02.003","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Vascular Surgery. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}